Table 2.

Characteristics of All Pseudomonas aeruginosa Posttraumatic Osteomyelitis Episodes Followed up, April 2018 to January 2022, Médecins Sans Frontières–Supported Facilities in Mosul (Iraq) and Gaza (Palestine)

Characteristic per PAPTO Episode	Total Episodes (n = 66)	Mosul (n = 21)	Gaza (n = 45)	P Valuea
Hospitalization and clinical characteristics
Length of stay, d, median (IQR)	42 (24–53)	30 (21–48)	43 (24–60)	.30
Surgical interventions, median (IQR)	2 (1–5)	4 (1–6)	1 (1–5)	.05
Clinical signs of infection at admission
Yes	62 (93.9)	21 (100.0)	41 (91.1)	.30
No	4 (6.1)	0 (0.0)	4 (8.9)
Months of follow-up during study period
≤6 mo	28 (46.7)	13 (68.4)	15 (36.6)	.02
>6 mo	32 (53.3)	6 (31.6)	26 (63.4)
Days completed under follow-up, median (IQR)	203 (72–443)	86 (24–213)	294 (111–475)	.01
Time from injury to first biopsy, d, median (IQR)	357 (37–698)	394 (20–1153)	324 (45–635)	.27
Biopsy-related characteristics
Bone samples collected per episode, median (IQR)	5 (4–5)	4 (3–5)	5 (4–5)	.01
Time from sample collection to biopsy results, d, median (IQR)	5 (4–7)	4 (3–4)	6 (4–8)	<.001
Length of treatment, d, mean (SD)	45.5 (15.6)	39.4 (9.6)	48.4 (17.1)	.032
Infection-related characteristics
Polymicrobial
Yes	49 (74.2)	12 (57.1)	37 (82.2)	.03
No	17 (25.8)	9 (42.9)	8 (17.8)
Multidrug-resistant PTOb
Yes	43 (65.1)	12 (57.1)	31 (68.9)	.35
No	23 (34.8)	9 (42.9)	14 (31.1)
Multidrug-resistant PAPTO
Yes	25 (37.9)	4 (19.0)	21 (46.7)	.06
No	41 (62.1)	17 (81.0)	24 (53.3)

Data are presented as No. (%) unless otherwise indicated.

Abbreviations: IQR, interquartile range; PAPTO, posttraumatic osteomyelitis caused by Pseudomonas aeruginosa; PTO, posttraumatic osteomyelitis; SD, standard deviation.

^a P < .05 is statistically significant.

^bCalculated among recurrent infections including non-PAPTO (new infections isolated from PAPTO patients, caused by bacteria other than P aeruginosa).